Advances in aerosol technology have improved drug delivery efficiency during noninvasive ventilation (NIV). Clinical evaluation of the efficacy of aerosol therapy during NIV in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) is very limited. The aim of our study was to compare the efficacy of bronchodilators administered through a vibrating mesh nebulizer (VMN) and jet nebulizer (JN) during NIV in patients with acute exacerbation of COPD.
Methods:
Prospective randomized cross-over study included 30 patients treated with NIV for acute exacerbation of COPD in an acute care hospital. Patients were consented and enrolled after stabilization of acute exacerbation (3–5 days after admission). Subjects were randomly assigned into two treatment arms receiving salbutamol (2.5 mg): with VMN (Aerogen Solo) and JN (Sidestream) positioned between the leak port and the nonvented oronasal mask during bilevel ventilation with a single-limb circuit. Measurements (clinical data, pulmonary function tests [PFTs], and arterial blood gases) were performed at baseline, 1, and 2 hours after treatment.
Results:
All measured PFT parameters significantly increased in both groups, but numerically results were better after inhalation with VMN than with JN: for forced expiratory volume in 1 second (FEV1) (mean increase from baseline to 120 minutes—165 ± 64 mL vs. 116 ± 46 mL, p = 0.001) and for forced vital capacity (FVC) (mean increase—394 ± 154 mL vs. 123 ± 57 mL, p < 0.001). There was also a statistically significant reduction in respiratory rate and in Borg dyspnea score after therapy with VMN in comparison with the conventional JN. In both groups, there were improvements in PaCO2, but with VMN these changes were significantly higher.
Conclusion:
Bronchodilator administration in patients with acute exacerbation of COPD during NIV with VMN resulted in clinically significant improvements in FVC and in Borg dyspnea score. Additional studies required to determine the impact on clinical outcomes.
RochwergB, BrochardL, ElliottMW, HessD, HillNS, NavaS, NavalesiP, AntonelliM, BrozekJ, ContiG, FerrerM, GuntupalliK, JaberS, KeenanS, ManceboJ, MehtaS, and RaoofS: Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017; 50:1602426.
3.
WedzichaJA, MiravitllesM, HurstJR, CalverleyPM, AlbertRK, AnzuetoA, CrinerGJ, PapiA, RabeKF, RigauD, SliwinskiP, ToniaT, VestboJ, WilsonKC, and KrishnanJA: Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017; 49:1600791.
4.
BrochardL, ManceboJ, WysockiM, LofasoF, ContiG, RaussA, SimonneauG, BenitoS, GasparettoA, and LemaireF: Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995; 333:817–822.
5.
PlantPK, OwenJL, and ElliottMW: Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial. Lancet. 2000; 355:1931–1935.
6.
OsadnikCR, TeeVS, Carson-ChahhoudKV, PicotJ, WedzichaJA, and SmithBJ: Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 7:CD004104.
7.
SalmeronS, BrochardL, MalH, TenaillonA, Henry-AmarM, RenonD, DurouxP, and SimonneauG: Nebulized vs intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. Am J Respir Crit Care Med. 1994; 149:1466–1470.
8.
ManceboJ, AmaroP, LorinoH, LemaireF, HarfA, and BrochardL: Effects of albuterol inhalation on the work of breathing during weaning from mechanical ventilation. Am Rev Respir Dis. 1991; 144:95–100.
9.
CerianaP, NavalesiP, RampullaC, PrinianakisG, and NavaS: Use of bronchodilators during non-invasive mechanical ventilation. Monaldi Arch Chest Dis. 2003; 59:123–127.
10.
ThilleAW, BertholonJ-F, BecqueminM-H, RoyM, LyazidiA, LelloucheF, PertusiniE, BoussignacG, MaitreB, and BrochardL: Aerosol delivery and humidification with the Boussignac continuous positive airway pressure device. Respir Care. 2011; 56:1526–1532.
11.
AriA, and FinkJB: Differential medical aerosol device and interface selection in patients during spontaneous, conventional mechanical and noninvasive ventilation. J Aerosol Med Pulm Drug Deliv. 2016; 29:95–106.
12.
EhrmannS, Roche-CampoF, Bodet-Contentin, RazaziK, DugernierJ, Trenado-AlvarezJ, DonzeauA, VermeulenF, ThevozD, PapanikolaouM, EdelsonA, YoshidoHL, PiquilloudL, LakhalK, LopesC, VicentC, DesachyA, Apiou-SbirleaG, IsabeyD, Brochard L; Reva Research NetworkAT, @ICU StudyGroup: Aerosol therapy in intensive and intermediate care units: Prospective observation of 2,808 critically ill patients. Intensive Care Med. 2016; 42:192–201.
13.
MukhopadhyayA, Dela PenaE, WaddenB, ProcyshynM, and LimTK: Effects of inhalational bronchodilator treatment during noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations. J Crit Care. 2009; 24:474.e1–e474.e5.
14.
PollackC, FleischK, and DowseyK: Treatment of acute bronchospasm with b-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Ann Emerg Med. 1995; 26:552–557.
15.
FaurouxB, IttiE, PigeotJ, IsabeyD, MeignanM, FerryG, LofasoF, WillemotJM, ClementA, and HarfA: Optimization of aerosol deposition by pressure support in children with cystic fibrosis: An experimental and clinical study. Am J Respir Crit Care Med. 2000; 162:2265–2271.
16.
NavaS, KarakurtS, RampullaC, BraschiA, and FanfullaF: Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: A randomized, controlled study. Intensive Care Med. 2001; 27:1627–1635.
17.
BrandaoDC, LimaVM, FilhoVG, SilvaTS, CamposTF, DeanE, and de AndradeAD: Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma. J Asthma. 2009; 46:356–361.
18.
Bodet-ContentinL, GuillonA, BoulainT, FratJP, GarotD, Le PennecD, VecellioL, EhrmannS, GiraudeauB, TavernierE, and DequinPF: Salbutamol nebulization during noninvasive ventilation in exacerbated chronic obstructive pulmonary disease patients: A randomized controlled trial. J Aerosol Med Pulm Drug Deliv. 2019; 32:149–155.
19.
ChatmongkolchartS, SchettinoGP, DillmanC, KacmarekRM, and HessDR: In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: Effect of ventilator settings and nebulizer position. Crit Care Med. 2002; 30:2515–2519.
20.
BranconnierMP, and HessDR: Albuterol delivery during noninvasive ventilation. Respir Care. 2005; 50:1649–1653.
21.
AbdelrahimME, PlantP, and ChrystynH: In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol. 2010; 62:966–972.
22.
SutherasanY, BallL, RaimondoP, CarattoV, SanguinetiE, Costantino, FerrettiM, KacmarekRM, and PelosiP: Effects of ventilator settings, nebulizer and exhalation port position on albuterol delivery during non-invasive ventilation: An in-vitro study. BMC Pulm Med. 2017; 17:9.
23.
SaeedH, MohsenM, Salah EldinA, ElberryAA, HusseinRR, RabeaH, and AbdelrahimME: Effects of fill volume and humidification on aerosol delivery during single-limb noninvasive ventilation. Respir Care. 2018; 63:1370–1378.
24.
EhrmannS: Vibrating mesh nebulisers—Can greater drug delivery to the airways and lungs improve respiratory outcomes?. Eur Respir Pulm Dis. 2018; 4:33–43.
25.
AbdelrahimME, PlantPK, and ChrystynH: The relative lung and systemic bioavailability of terbutaline following nebulisation in non-invasively ventilated patients. Int J Pharm. 2011; 420:313–318.
26.
MichotteJB, JossenE, RoeselerJ, LiistroG, and ReychlerG: In vitro comparison of five nebulizers during noninvasive ventilation: Analysis of inhaled and lost doses. J Aerosol Med Pulm Drug Deliv. 2014; 27:430–440.
27.
Galindo-FilhoVC, BrandaoDC, Ferreira R deC, MenezesMJ, Almeida-FilhoP, ParreiraVF, SilvaTN, Rodrigues-Machado M daG, DeanE, and Dornelas de AndradeA: Noninvasive ventilation coupled with nebulization during asthma crises: A randomized controlled trial. Respir Care. 2013; 58:241–249.
28.
HassanA, Salah EldinR, AbdelrahmanMM, and AbdelrahimME: In-vitro/in-vivo comparison of inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during non-invasive ventilation. Exp Lung Res. 2017; 43:19–28.
29.
AlQuaimiMM, FinkJB, and AriA: Efficiency of different aerosol devices and masks during noninvasive positive pressure ventilation in a simulated adult lung model. J Respir Med Lung Dis. 2017; 2:1018.
30.
MoustafaIOF, AliMRA, Al HallagM, RabeaH, FinkJB, DaileyP, and AbdelrahimMEA: Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients. Heart Lung. 2017; 46:464–467.
31.
LinH-L, FangT-P, ChoH-S, WanG-H, HsiehM-J, and FinkJB: Aerosol delivery during spontaneous breathing with different types of nebulizers-in vitro/ex vivo models evaluation. Pulm Pharmacol Ther. 2018; 48:225–231.
32.
Galindo-FilhoVC, AlcoforadoL, RattesC, PaivaDN, BrandãoSCS, FinkJB, and Dornelas de AndradeA: A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols. Respir Med. 2019; 153:60–67.
33.
MillerMR, HankinsonJ, BrusascoV, BurgosF, CasaburiR, CoatesA, CrapoR, EnrightP, van der GrintenCPM, GustafssonP, JensenR, JohnsonDC, MacIntyreN, McKayR, NavajasD, PedersenOF, PellegrinoR, ViegiG, WangerJ, and ATS/ERS TaskForce: Standardization of spirometry. Eur Respir J. 2005; 26:319–338.
34.
BorgG: Ratings of perceived exertion and heart rates during short-term cycle exercise and their use in a new cycling strength test. Int J Sports Med. 1982; 3:153–158.
35.
SinghS, Kanbar-AghaF, and SharafkhanehA: Novel aerosol delivery devices. Semin Respir Crit Care Med. 2015; 36:543–551.
36.
CushenB, AlsaidA, AbdulkareemA, and CostelloRW: Pilot study to assess bronchodilator response during an acute exacerbation of COPD using a vibrating mesh nebuliser versus jet nebuliser for bronchodilator delivery. Thorax. 2016; 71(Suppl. 3):P292.
37.
DunneRB, and ShorttS: Comparison of bronchodilator administration with vibrating mesh nebulizer and standard jet nebulizer in the emergency department. Am J Emerg Med. 2018; 36:641–646.
38.
StevensonNJ, WalkerPP, CostelloRW, and CalverleyPM: Lung mechanics during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172:1510–1516.
39.
BédardM-E, BrouillardC, PepinV, ProvencherS, MilotJ, LacasseY, LeblancP, and MaltaisF: Tiotropium improves walking endurance in COPD. Eur Respir J. 2012; 39:265–271.
40.
VignaM, AielloM, BertorelliG, CrisafulliE, and ChettaA: Flow and volume response to bronchodilator in patients with COPD. Acta Biomed. 2018; 89:332–336.
41.
TashkinDP, CelliB, DecramerM, LiuD, BurkhartD, CassinoC, and KestenS: Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008; 31:742–750.
42.
Pinto-PlataVM, LivnatG, GirishM, CabralH, MasdinP, LinacreP, DewR, KenneyL, and CelliBR: Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbations of COPD. Chest. 2007; 131:37–43.
